Recent

% | $
Quotes you view appear here for quick access.

Amarantus Bioscience Holdings, Inc Message Board

  • nidan7500 nidan7500 Jun 19, 2014 7:26 AM Flag

    Compelling is a great word to use in this context

    Cannot get this out of my head..."We believe this data will be the most compelling for Key Opinion Leaders (KOLs) and pharmaceutical companies, our target market for the initial launch of LymPro, as this will provide longitudinal data regarding LymPro’s performance and diagnostic integrity"

    He is saying I think that the retrospective review will be powerful. Massive and compelling in it's consequence. He wants to let that sink in, then talk to the diagnostic tools and applications second. Academics and clinicians will move from not knowing what they don't know to knowing what they don't know on the path to treatment of AD.

    This is what we are witnessing (IMO) from a basic learning process perspective. Instead of sitting around in the dark trying to treat AD we may be witnessing a breakthrough. This opinion based on the belief that there are enough really smart people around who(KOL), if given the right tools, will cure this thing. Maybe I have too much faith in GC but that is what I read with his comment

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
AMBS
0.0491+0.0020(+4.25%)May 4 3:59 PMEDT